HuGE Literature Finder
Records
1
-
2
Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Blood advances 2017 Sep 1 (20): 1729-1738. Spiegel Jay Y, McNamara Caroline, Kennedy James A, Panzarella Tony, Arruda Andrea, Stockley Tracy, Sukhai Mahadeo, Thomas Mariam, Bartoszko Justyna, Ho Jenny, Siddiq Nancy, Maze Dawn, Schimmer Aaron, Schuh Andre, Sibai Hassan, Yee Karen, Claudio Jamie, Devlin Rebecca, Minden Mark D, Kamel-Reid Suzanne, Gupta Vik |
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 2014 Apr 123 (14): 2157-60. Guglielmelli Paola, Biamonte Flavia, Rotunno Giada, Artusi Valentina, Artuso Lucia, Bernardis Isabella, Tenedini Elena, Pieri Lisa, Paoli Chiara, Mannarelli Carmela, Fjerza Rajmonda, Rumi Elisa, Stalbovskaya Viktoriya, Squires Matthew, Cazzola Mario, Manfredini Rossella, Harrison Claire, Tagliafico Enrico, Vannucchi Alessandro M, , |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 10, 2022
- Content source: